🇺🇸 FDA
Pipeline program

TAK-861

TAK-861-3002

Phase 3 small_molecule active

Quick answer

TAK-861 for Narcolepsy Type 1 is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 4 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Narcolepsy Type 1
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials